<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35360925</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1744-8298</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>18</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Future cardiology</Title>
          <ISOAbbreviation>Future Cardiol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Real-world evidence comparing oral anticoagulants in non-valvular atrial fibrillation: a systematic review and network meta-analysis.</ArticleTitle>
        <Pagination>
          <StartPage>393</StartPage>
          <EndPage>405</EndPage>
          <MedlinePgn>393-405</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2217/fca-2021-0120</ELocationID>
        <Abstract>
          <AbstractText><b>Aim:</b> To compare real-world effectiveness/safety of non-vitamin K antagonist oral anticoagulants and vitamin K antagonists among patients with non-valvular atrial fibrillation. <b>Materials &amp; methods:</b> A systematic review of electronic databases yielded 7661 citations published from January 2013 to January 2020. Fifty-five studies were included in Bayesian network meta-analyses of hazard ratios. <b>Results &amp; conclusion:</b> In comparison with vitamin K antagonists, apixaban, dabigatran and rivaroxaban were associated with a reduced risk of stroke or systemic embolism, ischemic stroke, intracranial hemorrhage and all-cause mortality. Apixaban, dabigatran and edoxaban, but not rivaroxaban, were associated with a reduced risk of major bleeding. This study confirmed the effectiveness and safety of non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation in real-world settings, consistent with clinical trial evidence.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Deitelzweig</LastName>
            <ForeName>Steven</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-5639-6484</Identifier>
            <AffiliationInfo>
              <Affiliation>Ochsner Health System, Department of Hospital Medicine, New Orleans, LA 70121, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bergrath</LastName>
            <ForeName>Evelien</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0002-4351-4170</Identifier>
            <AffiliationInfo>
              <Affiliation>Regeneron Pharmaceuticals, Inc., Health Economics and Outcomes Research, Tarrytown, NY 10591, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>di Fusco</LastName>
            <ForeName>Manuela</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0003-0079-7331</Identifier>
            <AffiliationInfo>
              <Affiliation>Pfizer, Inc., Health Economics and Outcomes Research, New York, NY 10017, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kang</LastName>
            <ForeName>Amiee</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Bristol Myers Squibb Company, Health Economics and Outcomes Research, Lawrenceville, NJ 08648, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Savone</LastName>
            <ForeName>Mirko</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Pfizer, Inc., Health Economics and Outcomes Research, New York, NY 10017, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cappelleri</LastName>
            <ForeName>Joseph C</ForeName>
            <Initials>JC</Initials>
            <Identifier Source="ORCID">0000-0001-9586-0748</Identifier>
            <AffiliationInfo>
              <Affiliation>Pfizer, Inc., Health Economics and Outcomes Research, New York, NY 10017, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Russ</LastName>
            <ForeName>Cristina</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0001-7248-9712</Identifier>
            <AffiliationInfo>
              <Affiliation>Pfizer, Inc., Health Economics and Outcomes Research, New York, NY 10017, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Betts</LastName>
            <ForeName>Marissa</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-0557-3946</Identifier>
            <AffiliationInfo>
              <Affiliation>Evidera, Evidence Synthesis, Modeling &amp; Communication, Waltham, MA 02451, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cichewicz</LastName>
            <ForeName>Allie</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-8528-9901</Identifier>
            <AffiliationInfo>
              <Affiliation>Evidera, Evidence Synthesis, Modeling &amp; Communication, Waltham, MA 02451, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schaible</LastName>
            <ForeName>Kassandra</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Evidera, Evidence Synthesis, Modeling &amp; Communication, Waltham, MA 02451, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tarpey</LastName>
            <ForeName>Jialu</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Evidera, Evidence Synthesis, Modeling &amp; Communication, Waltham, MA 02451, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fahrbach</LastName>
            <ForeName>Kyle</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0003-2879-2663</Identifier>
            <AffiliationInfo>
              <Affiliation>Evidera, Evidence Synthesis, Modeling &amp; Communication, Waltham, MA 02451, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Future Cardiol</MedlineTA>
        <NlmUniqueID>101239345</NlmUniqueID>
        <ISSNLinking>1479-6678</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005343">Fibrinolytic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011728">Pyridones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>12001-79-5</RegistryNumber>
          <NameOfSubstance UI="D014812">Vitamin K</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9NDF7JZ4M3</RegistryNumber>
          <NameOfSubstance UI="D000069552">Rivaroxaban</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>I0VM4M70GC</RegistryNumber>
          <NameOfSubstance UI="D000069604">Dabigatran</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001281" MajorTopicYN="Y">Atrial Fibrillation</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001499" MajorTopicYN="N">Bayes Theorem</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069604" MajorTopicYN="N">Dabigatran</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005343" MajorTopicYN="N">Fibrinolytic Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071076" MajorTopicYN="N">Network Meta-Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011728" MajorTopicYN="N">Pyridones</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069552" MajorTopicYN="N">Rivaroxaban</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020521" MajorTopicYN="Y">Stroke</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014812" MajorTopicYN="N">Vitamin K</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <OtherAbstract Type="plain-language-summary" Language="eng">
        <AbstractText>This study aimed to compare real-world effectiveness/safety of non-vitamin K antagonist oral anticoagulants and vitamin K antagonists among patients with non-valvular atrial fibrillation. A systematic review was conducted from January 2013 to January 2020, and a total of 7661 references were assessed for relevance. Fifty-five studies were combined in the analysis; in comparison with vitamin K antagonists, apixaban, dabigatran and rivaroxaban were associated with a reduced risk of stroke or systemic embolism, ischemic stroke, intracranial hemorrhage and all-cause mortality. Apixaban, dabigatran and edoxaban, but not rivaroxaban, were associated with a reduced risk of major bleeding. This study confirmed the effectiveness and safety of non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation in real-world settings, consistent with clinical trial evidence.</AbstractText>
      </OtherAbstract>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">network meta-analysis</Keyword>
        <Keyword MajorTopicYN="Y">non-valvular atrial fibrillation</Keyword>
        <Keyword MajorTopicYN="Y">non-vitamin K antagonist oral anticoagulants</Keyword>
        <Keyword MajorTopicYN="Y">real-world evidence</Keyword>
        <Keyword MajorTopicYN="Y">systematic review</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>5</Hour>
          <Minute>30</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35360925</ArticleId>
        <ArticleId IdType="doi">10.2217/fca-2021-0120</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
